October 14, 2024 01:58 PM EDT
FDA+

No­var­tis used a PRV to speed Kisqal­i's lat­est in­di­ca­tion, FDA says

Zachary Brennan

Senior Editor

No­var­tis used one of its pri­or­i­ty re­view vouch­ers (PRV) to speed the Sep­tem­ber ap­proval of Kisqali in ear­ly breast can­cer, the FDA said Mon­day. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

Two GSK tri­als with long-act­ing drug in chron­ic rhi­nos­i­nusi­tis hit pri­ma­ry end­points

Pfiz­er de­tails re­sults from failed Phase 3 tri­al of Duchenne mus­cu­lar dy­s­tro­phy gene ther­a­py 

No­var­tis ends mid-stage IPF tri­al, will keep test­ing drug in PAH

Up­dat­ed: Lund­beck makes $2.6B cash move for Long­board a month af­ter start­ing Phase 3 in Dravet syn­drome

No­vo Nordisk files 18 law­suits against GLP-1 com­pounders in 44 days

sponsored

Join the Gen­Script Biotech Glob­al Fo­rum: Un­lock­ing In­no­va­tions in Cell and Gene Ther­a­pies

A service from the Financial Times